Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Pediatr Gastroenterol Nutr ; 55(1): 76-81, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22241510

ABSTRACT

BACKGROUND AND AIM: Patients with cystic fibrosis (CF) have low levels of n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) in plasma or red blood cells (RBC), as also seen in other chronic and acute liver diseases. The differences may be more pronounced in CF transmembrane conductance regulator protein (CFTR)-regulated tissues such as granulocytes, monocytes, and lymphocytes. The aim of the present study was to investigate whether patients with CF-related liver disease have lower n-3 LCPUFA level than patients with CF without liver disease. METHODS: Twenty patients with known CF-related liver disease were matched with 20 CF patients without. Blood samples were analysed for liver biochemistry and haematology. Granulocytes, mononuclear cells, and RBC were separated by density gradient centrifugation, and fatty acid composition was measured by gas chromatography. Hepatic ultrasound was scored according to Williams et al. Hepatic transit time (HTT) was measured with the ultrasound contrast agent SonoVue. RESULTS: No significant differences were seen in either n-6 or n-3 LCPUFAs in any cell line when the 2 groups were compared. In a multiple regression analysis including HTT, age, Pseudomonas aeruginosa infection, diabetes mellitus, treatment with ursodeoxycholic acid, forced expiratory volume in 1 second (% of predicted value), and Williams' ultrasound scoring scale, only n-3 LCPUFA docosahexaenoic acid in mononuclear cell membranes was positively associated with HTT (P = 0.02). The arachidonic acid/docosahexaenoic acid ratio within the mononuclear cells was negatively associated with both HTT (P = 0.003) and Williams' ultrasound scoring scale (P = 0.03). For RBC-LCPUFAs, no significant associations were seen. CONCLUSIONS: These findings indicate that in patients with CF, the degree of liver disease was negatively associated with LCPUFA n-3 levels in CFTR-expressing white blood cells but unrelated to those levels in CFTR-negative RBC.


Subject(s)
Cystic Fibrosis/blood , Erythrocytes/chemistry , Fatty Acids, Unsaturated/analysis , Granulocytes/chemistry , Leukocytes, Mononuclear/chemistry , Liver Diseases/blood , Adolescent , Adult , Alanine Transaminase/blood , Animals , Arachidonic Acid/analysis , Aspartate Aminotransferases/blood , Bilirubin/blood , Child , Child, Preschool , Cystic Fibrosis/complications , Diet , Docosahexaenoic Acids/analysis , Eicosapentaenoic Acid/analysis , Fatty Acids, Omega-3 , Female , Fishes , Humans , Liver Diseases/complications , Liver Diseases/diagnostic imaging , Male , Oleic Acid/analysis , Surveys and Questionnaires , Ultrasonography , Young Adult
2.
Diabetes Care ; 29(12): 2660-3, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17130201

ABSTRACT

OBJECTIVE: Cystic fibrosis (CF)-related diabetes has been regarded as a mild form of diabetes with a low risk of severe diabetes complications. The prevalence of CF-related diabetes increases with age, resulting in a 50% prevalence of diabetes at age 30 years. We sought to investigate whether microvascular complications in CF-related diabetes appear with a relevant frequency. RESEARCH DESIGN AND METHODS: Thirty-eight patients aged 30 (range 18-55) years with CF-related diabetes for 20 (0-31) years were screened for diabetes complications. Because of chronic pulmonary infections, the majority of patients were regularly treated with aminoglycoside and cyclosporine given frequently. RESULTS: Since the pharmacological treatment of lung transplant patients could influence metabolical regulation and renal function, the results are given separately for nontransplanted (n = 29) and transplanted (n = 9) CF patients. Nine patients (27%) had retinopathy, two of which had proliferative retinopathy and needed laser treatment. Lung transplantation did not affect the prevalence of retinopathy. In nontransplanted patients, nine had hypertension, three microalbuminuria, and one elevated creatinine. None had macroalbuminuria. In transplanted patients, eight of nine had hypertension, two had microalbuminuria, and none had macroalbuminuria. Seven of nine lung transplant patients had elevated plasma creatinine, and severely reduced glomerular filtration rate was significantly more frequent. CONCLUSIONS: A high frequency of diabetic retinopathy was found in patients with insulin-treated CF-related diabetes, stressing the need for a regular screening program as in type 1 diabetes. Severely impaired kidney function was common in lung transplant patients, probably secondary to cyclosporine treatment.


Subject(s)
Cystic Fibrosis/complications , Diabetic Angiopathies/epidemiology , Diabetic Retinopathy/epidemiology , Microcirculation , Adolescent , Adult , Diabetic Nephropathies/epidemiology , Female , Humans , Male , Middle Aged , Prevalence , Visual Acuity
3.
APMIS ; 113(6): 400-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15996157

ABSTRACT

The inflammation in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa lung infection is dominated by polymorphonuclear neutrophils (PMNs). There seems to be a relationship between the PMN-dominated inflammation, pronounced antibody production and a Th2-dominated response. Apart from mobilizing monocytes and PMNs from the bone marrow, GM-CSF, G-CSF and IL-3 select subsets of dendritic cells, which subsequently induce distinct Th responses. Therefore, the present study examines the correlation between the mobilizing cytokines in serum and the Th responses. The IFN-gamma and IL-4 production by peripheral blood mononuclear cells, and the concentrations of GM-CSF and G-CSF in serum as well as lung function, were determined in 37 CF patients with and 6 CF patients without chronic P. aeruginosa lung infection. The GM-CSF/G-CSF ratio correlated both with the IFN-gamma production and good lung function. In addition, an inverse correlation between IL-3 and IFN-gamma was observed. The results indicate involvement of endogenous GM-CSF, G-CSF and IL-3 in the skewed Th response in CF, and change to a Th1-dominated response might be achieved with GM-CSF treatment.


Subject(s)
Cystic Fibrosis/diagnosis , Granulocyte Colony-Stimulating Factor/blood , Granulocyte-Macrophage Colony-Stimulating Factor/blood , Pneumonia, Bacterial/diagnosis , Pseudomonas Infections/diagnosis , Th1 Cells/immunology , Th2 Cells/immunology , Adolescent , Adult , Chronic Disease , Cystic Fibrosis/blood , Cystic Fibrosis/complications , Cytokines/blood , Female , Humans , Male , Pneumonia, Bacterial/blood , Pneumonia, Bacterial/complications , Prognosis , Pseudomonas Infections/blood , Pseudomonas Infections/complications , Pseudomonas aeruginosa
4.
Pediatr Pulmonol ; 33(3): 201-7, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11836800

ABSTRACT

Deficiency of mannose-binding lectin has been shown to be a risk factor for cystic fibrosis (CF) patients. We, therefore, decided to treat a patient with CF, mannose-binding lectin deficiency, severe bronchopulmonary Pseudomonas aeruginosa infection, and rapid deterioration of lung function with purified mannose-binding lectin in an attempt to ameliorate the course of the lung disease. The mannose-binding lectin used originated from pooled human donor plasma and was given as an intravenous infusion twice a week for a period of 3 months. The patients's clinical condition was stabilized during the treatment period, but was not improved. No adverse events were observed. However, the lung function assessed as percent forced expiratory volume in 1 sec (FEV1%) and percent forced vital capacirt (FVC%) correlated significantly with the mannose-binding serum lectin levels (rho=+0.68, P=0.008, and rho=+0.73, P=0.004). Additionally, an inverse correlation with the acute phase-reactant C-reactive protein and the proinflammatory cytokine IL-6 was observed (rho=-0.49, P=0.007 and rho=-0.41, P=0.04, respectively). The results emphasize the importance of mannose-binding lectin as a secondary disease modifier in CF. Moreover, purified mannose-binding lectin can safely be administered to chronically ill patients, and may be a potential treatment in CF and other diseases in which mannose-binding lectin deficiency plays a pathophysiological role.


Subject(s)
Carrier Proteins/therapeutic use , Cystic Fibrosis/drug therapy , Adult , Alleles , C-Reactive Protein/metabolism , Carrier Proteins/genetics , Carrier Proteins/metabolism , Collectins , Cystic Fibrosis/complications , Cystic Fibrosis/genetics , Disease Progression , Drug Therapy, Combination , Fatal Outcome , Female , Forced Expiratory Volume , Humans , Interleukin-6/metabolism , Mutation , Pseudomonas Infections/complications , Spirometry , Tumor Necrosis Factor-alpha/metabolism , Vital Capacity
SELECTION OF CITATIONS
SEARCH DETAIL
...